French biotech company BioAlliance Pharma has submitted a marketing application to the EMEA, and the European regulatory authority will now have to decide whether or not to green-light the drug ondansentron, a treatment for preventing and treating nausea and vomiting in cancer patients that have received radiation and chemotherapy. The company made the submission under the EU's decentralized procedure. The dissolving oral-film strip formulation of the serotonin (5-HT3) receptor antagonist uses RapidFilm drug delivery technology developed by Swiss Applied Pharma Research and Germany’s Labtec, a subsidiary of Hamburg-based tape manufacturer Tesa. BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. In France, the company has launched its first drug -- Loramyc, a substance for treating oropharyngeal candidiasis (“thrush”). It also has two other compounds currently in Phase III clinical trials: the acyclovir compound Lauriad for oral herpes, and the doxorubicin Transdrug for primary liver cancer.